EA201101704A1 - ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА - Google Patents

ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА

Info

Publication number
EA201101704A1
EA201101704A1 EA201101704A EA201101704A EA201101704A1 EA 201101704 A1 EA201101704 A1 EA 201101704A1 EA 201101704 A EA201101704 A EA 201101704A EA 201101704 A EA201101704 A EA 201101704A EA 201101704 A1 EA201101704 A1 EA 201101704A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazo
quinolinone
derivatives
treatment
diseases
Prior art date
Application number
EA201101704A
Other languages
English (en)
Other versions
EA020715B1 (ru
Inventor
Паскаль Фюре
Франк Штефан Кальтхофф
Роберт Ма
Кристиан Раго
Фредерик Штауффер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101704(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201101704A1 publication Critical patent/EA201101704A1/ru
Publication of EA020715B1 publication Critical patent/EA020715B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению производных 1Н-имидазо[4,5-с]хинолинона и их солей для лечения заболеваний, зависимых от протеин- и/или липидкиназы, и для приготовления фармацевтических препаратов, предназначенных для лечения таких заболеваний; производные 1Н-имидазо[4,5-с]хинолинона, предназначенные для применения для лечения заболеваний, зависимых от протеин- и/или липидкиназы; способ лечения указанных заболеваний, включающий введение производных 1H-имидазо[4,5-с]хинолинона теплокровному животному, предпочтительно человеку; фармацевтические препараты, содержащие производное 1H-имидазо[4,5-с]хинолинона, предпочтительно предназначенные для лечения заболевания, зависимого от протеин- и/или липидкиназы; новые производные 1H-имидазо[4,5-с]хинолинона; и способ получения новых производных 1H-имидазо[4,5-с]хинолинона.
EA201101704A 2009-06-04 2010-06-02 ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА EA020715B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04
PCT/EP2010/057719 WO2010139731A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Publications (2)

Publication Number Publication Date
EA201101704A1 true EA201101704A1 (ru) 2012-07-30
EA020715B1 EA020715B1 (ru) 2015-01-30

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101704A EA020715B1 (ru) 2009-06-04 2010-06-02 ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА

Country Status (30)

Country Link
US (2) US8476294B2 (ru)
EP (1) EP2438064A1 (ru)
JP (1) JP5596137B2 (ru)
KR (1) KR101445458B1 (ru)
CN (1) CN102574845B (ru)
AR (1) AR076949A1 (ru)
AU (1) AU2010255727B2 (ru)
BR (1) BRPI1010621A2 (ru)
CA (1) CA2763821A1 (ru)
CL (1) CL2011003052A1 (ru)
CO (1) CO6470887A2 (ru)
CR (1) CR20110608A (ru)
CU (1) CU24064B1 (ru)
DO (1) DOP2011000373A (ru)
EA (1) EA020715B1 (ru)
EC (1) ECSP11011500A (ru)
GE (1) GEP20156267B (ru)
IL (1) IL216452A0 (ru)
MA (1) MA33332B1 (ru)
MX (1) MX2011012943A (ru)
NI (1) NI201100209A (ru)
NZ (1) NZ596487A (ru)
PE (1) PE20120224A1 (ru)
SG (1) SG176572A1 (ru)
TN (1) TN2011000626A1 (ru)
TW (1) TWI464168B (ru)
UA (1) UA106074C2 (ru)
UY (1) UY32682A (ru)
WO (1) WO2010139731A1 (ru)
ZA (1) ZA201108439B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN103402520A (zh) * 2010-12-06 2013-11-20 皮拉马尔企业有限公司 具有取代基的咪唑并喹啉衍生物
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
EP2781520B1 (en) * 2011-11-17 2016-05-04 Xuanzhu Pharma Co., Ltd. Three-ring pi3k and/or mtor inhibitor
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
KR102227271B1 (ko) 2013-04-15 2021-03-12 에프엠씨 코포레이션 살진균성 아미드
US9893299B2 (en) 2013-09-11 2018-02-13 Merck Patent Gmbh Heterocyclic compounds
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
JP6606428B2 (ja) * 2013-10-11 2019-11-13 国立大学法人 東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
AU2014352463B2 (en) 2013-11-20 2017-05-11 Beijing Forelandpharma Co. Ltd. Ketone derivatives of imidazoles, pharmaceutical combinations and uses thereof
NO2714752T3 (ru) 2014-05-08 2018-04-21
PT3152199T (pt) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd Compostos de pirazol e a sua utilização como bloqueadores de canais de cálcio do tipo t
TR201911244T4 (tr) * 2015-04-02 2019-08-21 Merck Patent Gmbh İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10988472B2 (en) 2016-10-13 2021-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
US11213517B2 (en) 2016-12-16 2022-01-04 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a T-type calcium channel blocker
TWI808960B (zh) 2017-02-06 2023-07-21 瑞士商愛杜西亞製藥有限公司 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
JP2021506978A (ja) 2017-12-22 2021-02-22 ラヴェンナ ファーマシューティカルズ，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
WO2005054237A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
US20080213308A1 (en) 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006311871B2 (en) 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
EA015677B1 (ru) 2006-11-20 2011-10-31 Новартис Аг СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
AU2008218806B2 (en) * 2007-02-20 2011-12-01 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US20100196365A1 (en) * 2007-07-24 2010-08-05 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
US20090082387A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
MX338088B (es) 2008-03-26 2016-04-01 Novartis Ag Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
CA2735932C (en) * 2008-09-30 2013-07-09 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
CR20110608A (es) 2012-01-16
UY32682A (es) 2011-01-31
AU2010255727A1 (en) 2011-12-08
KR20120034710A (ko) 2012-04-12
CL2011003052A1 (es) 2012-08-31
EP2438064A1 (en) 2012-04-11
SG176572A1 (en) 2012-01-30
IL216452A0 (en) 2012-01-31
NZ596487A (en) 2012-11-30
EA020715B1 (ru) 2015-01-30
CO6470887A2 (es) 2012-06-29
MA33332B1 (fr) 2012-06-01
GEP20156267B (en) 2015-04-14
JP2012528828A (ja) 2012-11-15
CN102574845A (zh) 2012-07-11
US8476294B2 (en) 2013-07-02
CN102574845B (zh) 2015-09-02
CU20110221A7 (es) 2012-03-15
TWI464168B (zh) 2014-12-11
DOP2011000373A (es) 2011-12-31
UA106074C2 (ru) 2014-07-25
AR076949A1 (es) 2011-07-20
KR101445458B1 (ko) 2014-10-07
CU24064B1 (es) 2014-12-26
NI201100209A (es) 2012-02-02
AU2010255727B2 (en) 2013-02-28
WO2010139731A1 (en) 2010-12-09
US20140005163A1 (en) 2014-01-02
ZA201108439B (en) 2012-08-29
US20100317657A1 (en) 2010-12-16
ECSP11011500A (es) 2012-01-31
TW201102386A (en) 2011-01-16
BRPI1010621A2 (pt) 2016-06-21
CA2763821A1 (en) 2010-12-09
TN2011000626A1 (en) 2013-05-24
MX2011012943A (es) 2012-01-27
JP5596137B2 (ja) 2014-09-24
PE20120224A1 (es) 2012-04-04

Similar Documents

Publication Publication Date Title
EA201101704A1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
BR0311221A (pt) Derivados de 1h-imidazo[4,5-c]quinolina no tratamento de doenças dependentes de proteìna cinase
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
BRPI0416796A (pt) compostos orgánicos
CY1117916T1 (el) Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
ATE400573T1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
BR112014005653A2 (pt) uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
CY1114276T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU